Antihyperglycemic activity of trigonelline and sitagliptin in nicotinamide-streptozotocin induced diabetes in Wistar rats - 18/09/13
Abstract |
The objective of the present study was to evaluate the protective effect of trigonelline (TRIG) and sitagliptin (SITA) combination in streptozotocin-nicotinamide induced diabetes in Wistar rats. Diabetes was induced by streptozotocin (65mg/kg i.p.) injected 15min after nicotinamide (110mg/kg, i.p.). The rats were divided into following groups: Group 1: non-diabetic control, Group 2: diabetic control (saline), Groups 3, 4, 5 received TRIG as 25, 50, 100mg/kg p.o., Groups 6, 7, 8 received SITA as 2.5, 5, 10mg/kg p.o. respectively. For acute study, serum glucose (SG) levels were measured at 0, 2nd, 4th, 6th and 24th hour after administration. To find out effective combination, acute study of TRIG+SITA combination was done. The doses used are in combination TRIG+SITA as Groups 9, 10, 11 as 70%+30%, 50%+50%, 30+70%. SG was measured as per above-mentioned pattern. A 28-day subacute study was performed by taking effective percentage combination of TRIG+SITA. For subacute study SG, body weight was measured on 7th, 14th, 21st, 28th day; while serum insulin, HbA1c and pancreatic histopathological study were done on 28th day. In acute study, TRIG+SITA (50%+50%) were more effectively 43.08% reduction in SG level at 6h with onset at 2h and effect waned at 24h. Subacute study reveals that the TRIG+SITA (50%+50%) reduces SG by 54.72% than alone on 28th day. Serum insulin levels, body weight, pancreatic mass were increased with reduction in HbA1c levels in animals receiving 50%+50% combination of TRIG+SITA. The concomitant administration of TRIG+SITA (50%+50%) contributes in the prevention to development diabetes and showed synergistic antihyperglycemic effect.
El texto completo de este artículo está disponible en PDF.Keywords : STZ-nicotinamide, Trigonelline, Sitagliptin, Serum glucose, Body weight, Serum insulin, Glycosylated hemoglobin (HbA1c), Pancreatic β-cells
Esquema
Vol 3 - N° 3
P. 125-130 - juillet 2013 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?